In 2012, Sharon Seibel was diagnosed with pancreatic cancer. Her surgical pathology showed extensive lymph-node involvement. Based on her BRCA2 mutation and low tumor burden, her brother Dr. Arnold Glazier, an inventor on nine patents related to drug design and chemistry, proposed a treatment based on melphalan.
Sharon received two cycles of melphalan at Tufts Medical Center in July and September 2012 and has received no pancreatic cancer treatment since. As of 2026, she remains free of pancreatic cancer. No chronic toxicities were reported following treatment.
Sharon’s case led to the founding of General Oncology in 2015. Today the company operates a laboratory in Newton, Massachusetts and is conducting the phase 1 SHARON clinical trial, with data presented at the ESMO 2025 Congress (view the poster).
A second drug candidate has completed preclinical pilot studies and is advancing toward IND-enabling studies, with a planned phase 1 trial targeting wet AMD or diabetic retinopathy expected in 2027. Additional pipeline programs are currently in synthesis.
